Nov 28, 2023 Vedanta Biosciences’ Key Microbiome Patents Fully Upheld in Three European Opposition Proceedings
Nov 13, 2023 Topline Data of Investigator-Sponsored Study of VE303 to Treat Hepatic Encephalopathy (HE) Presented at The Liver Meeting 2023
Oct 30, 2023 Vedanta Biosciences to Host Investor Meetings at the Wells Fargo Virtual Private Biotech Symposium
Oct 11, 2023 Vedanta Biosciences Presents Progress from Two Defined Bacterial Consortia, VE303 for the Prevention of C. difficile and VE707 for the Prevention of Gram-Negative Infections, at IDWeek 2023
Oct 4, 2023 Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation
May 8, 2023 Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
Apr 25, 2023 Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
Apr 17, 2023 Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID
